Acusphere (ACUS) Stock Price, News & Analysis

Company Overview

Acusphere, Inc. is a development-stage specialty pharmaceutical company that focuses on the design, development and licensing of proprietary drug delivery and formulation technologies. The company’s platforms aim to enhance solubility, stability and bioavailability for poorly water-soluble drug candidates, addressing challenges in therapeutic areas such as oncology and central nervous system disorders.

Rather than advancing products through costly late-stage clinical trials on its own, Acusphere pursues a partnering business model. Pharmaceutical and biotechnology companies can license rights to Acusphere’s patented technologies in exchange for upfront fees, development milestones and royalties on future product sales. This approach allows Acusphere to leverage its intellectual property portfolio while sharing development risk and cost with established industry players.

Founded in 1996 and incorporated in Delaware, Acusphere has built a portfolio of proprietary formulation platforms and method-of-use patents. Early efforts included work on selective COX-2 inhibitors, and the company has since expanded its pipeline through collaborations that extend its reach into multiple therapeutic areas. Acusphere maintains its principal operations in Florida.

Led by a management team with expertise in pharmaceutical development, regulatory affairs and intellectual property management, Acusphere seeks to maximize shareholder value by out-licensing its technologies to partners equipped to advance products into later stages of clinical development and commercialization.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACUS Stock Analysis - Frequently Asked Questions

How do I buy shares of Acusphere?

Shares of ACUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ACUS
• CIK: N/A
• Web: www.acusphere.com
• Phone: (617) 648-8800
• Fax: 978-863-9993
• Employees: 118
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -1.87